Italia markets closed

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
10,40+0,47 (+4,68%)
Al 03:45PM EST. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente9,93
Aperto9,90
Denaro10,36 x 800
Lettera10,37 x 800
Min-Max giorno9,64 - 10,44
Intervallo di 52 settimane9,59 - 33,70
Volume1.956.702
Media Volume1.571.817
Capitalizzazione714,791M
Beta (5 anni mensile)1,96
Rapporto PE (ttm)N/D
EPS (ttm)-2,73
Prossima data utili22 feb 2023 - 27 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A17,57
  • GlobeNewswire

    Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

    EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients Achieved proof of concept and identified a responder population In view of the small population, the Company will pause enrollment in the BRILLIANCE trial and seek to identify a collaboration partner to continue development of EDIT-101 Company to host a webinar today at 8:00 a.m. ET CAMBRIDGE, Mass.,

  • GlobeNewswire

    Editas Medicine Announces Third Quarter 2022 Results and Business Updates

    Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to provide a clinical update on the Phase 1/2 BRILLIANCE trial for EDIT-101 this month CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome edi

  • GlobeNewswire

    Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update

    CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of 2022. To access the conference call: U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.Participants s